Nurix Therapeutics, Inc.

NasdaqGM:NRIX Stock Report

Market Cap: US$1.4b

Nurix Therapeutics Management

Management criteria checks 4/4

Nurix Therapeutics' CEO is Arthur Sands, appointed in Sep 2014, has a tenure of 10.25 years. total yearly compensation is $4.36M, comprised of 13.5% salary and 86.5% bonuses, including company stock and options. directly owns 0.44% of the company’s shares, worth $6.11M. The average tenure of the management team and the board of directors is 4.5 years and 4.3 years respectively.

Key information

Arthur Sands

Chief executive officer

US$4.4m

Total compensation

CEO salary percentage13.5%
CEO tenure10.3yrs
CEO ownership0.4%
Management average tenure4.5yrs
Board average tenure4.3yrs

Recent management updates

Recent updates

Subdued Growth No Barrier To Nurix Therapeutics, Inc. (NASDAQ:NRIX) With Shares Advancing 25%

Nov 07
Subdued Growth No Barrier To Nurix Therapeutics, Inc. (NASDAQ:NRIX) With Shares Advancing 25%

Companies Like Nurix Therapeutics (NASDAQ:NRIX) Are In A Position To Invest In Growth

Oct 31
Companies Like Nurix Therapeutics (NASDAQ:NRIX) Are In A Position To Invest In Growth

Nurix: An Attractive Early-Stage Biotech Play

Oct 08

Unpleasant Surprises Could Be In Store For Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) Shares

Sep 07
Unpleasant Surprises Could Be In Store For Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) Shares

Nurix Therapeutics: Promising Science, Major Collaborations, Undifferentiated Data

Sep 04

Nurix Therapeutics (NASDAQ:NRIX) Is In A Good Position To Deliver On Growth Plans

Jul 15
Nurix Therapeutics (NASDAQ:NRIX) Is In A Good Position To Deliver On Growth Plans

Nurix Therapeutics: Protein Deg Specialist's Latest Data Establishes Bull Case

Jun 19

What Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 26% Share Price Gain Is Not Telling You

May 29
What Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 26% Share Price Gain Is Not Telling You

Nurix Therapeutics Advances Promising Protein Degraders For B-Cell Malignancies

Apr 15

Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 28% Price Boost Is Out Of Tune With Revenues

Apr 14
Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 28% Price Boost Is Out Of Tune With Revenues

Improved Revenues Required Before Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Find Their Feet

Feb 20
Improved Revenues Required Before Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Find Their Feet

Nurix Therapeutics: Recovering Thanks To ASH, But I Think It's Priced Just Right For Now

Jan 16

Here's Why We're Watching Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Situation

Dec 29
Here's Why We're Watching Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Situation

Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 29% Dip In Price Shows Sentiment Is Matching Revenues

Oct 14
Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 29% Dip In Price Shows Sentiment Is Matching Revenues

Broker Revenue Forecasts For Nurix Therapeutics, Inc. (NASDAQ:NRIX) Are Surging Higher

Oct 13
Broker Revenue Forecasts For Nurix Therapeutics, Inc. (NASDAQ:NRIX) Are Surging Higher

Here's Why We're Watching Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Situation

Sep 30
Here's Why We're Watching Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Situation

Party Time: Brokers Just Made Major Increases To Their Nurix Therapeutics, Inc. (NASDAQ:NRIX) Earnings Forecasts

Apr 18
Party Time: Brokers Just Made Major Increases To Their Nurix Therapeutics, Inc. (NASDAQ:NRIX) Earnings Forecasts

We Think Nurix Therapeutics (NASDAQ:NRIX) Needs To Drive Business Growth Carefully

Apr 15
We Think Nurix Therapeutics (NASDAQ:NRIX) Needs To Drive Business Growth Carefully

We're Keeping An Eye On Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Rate

Nov 28
We're Keeping An Eye On Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Rate

Nurix Therapeutics GAAP EPS of -$0.90 beats by $0.07, revenue of $10.79M misses by $1.29M

Oct 06

Nurix Therapeutics GAAP EPS of -$1.01 misses by $0.02, revenue of $11.43M beats by $0.93M

Jul 07

FDA approves expansion of Nurix Therapeutics' phase 1 trial of NX-1607 into the U.S.

Jun 30

We Think Nurix Therapeutics (NASDAQ:NRIX) Needs To Drive Business Growth Carefully

Jun 21
We Think Nurix Therapeutics (NASDAQ:NRIX) Needs To Drive Business Growth Carefully

We Think Nurix Therapeutics (NASDAQ:NRIX) Can Afford To Drive Business Growth

Mar 07
We Think Nurix Therapeutics (NASDAQ:NRIX) Can Afford To Drive Business Growth

Nurix: Advancing Targeted Protein Modulation Therapies

Nov 21

Companies Like Nurix Therapeutics (NASDAQ:NRIX) Can Afford To Invest In Growth

Nov 21
Companies Like Nurix Therapeutics (NASDAQ:NRIX) Can Afford To Invest In Growth

CEO Compensation Analysis

How has Arthur Sands's remuneration changed compared to Nurix Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Aug 31 2024n/an/a

-US$177m

May 31 2024n/an/a

-US$165m

Feb 29 2024n/an/a

-US$145m

Nov 30 2023US$4mUS$591k

-US$144m

Aug 31 2023n/an/a

-US$149m

May 31 2023n/an/a

-US$157m

Feb 28 2023n/an/a

-US$179m

Nov 30 2022US$9mUS$572k

-US$180m

Aug 31 2022n/an/a

-US$171m

May 31 2022n/an/a

-US$154m

Feb 28 2022n/an/a

-US$135m

Nov 30 2021US$5mUS$539k

-US$117m

Aug 31 2021n/an/a

-US$99m

May 31 2021n/an/a

-US$89m

Feb 28 2021n/an/a

-US$63m

Nov 30 2020US$17mUS$521k

-US$43m

Aug 31 2020n/an/a

-US$37m

May 31 2020n/an/a

-US$21m

Feb 29 2020n/an/a

-US$24m

Nov 30 2019US$1mUS$474k

-US$22m

Compensation vs Market: Arthur's total compensation ($USD4.36M) is about average for companies of similar size in the US market ($USD5.51M).

Compensation vs Earnings: Arthur's compensation has been consistent with company performance over the past year.

CEO

Arthur Sands (62 yo)

10.3yrs

Tenure

US$4,363,120

Compensation

Dr. Arthur T. Sands, M.D., Ph D., has been the Chief Executive Officer and Director of Nurix Therapeutics, Inc. (formerly, Nurix Inc.) since September 2014 and has been its President since June 2020. Dr. S...

Leadership Team

NamePositionTenureCompensationOwnership
Arthur Sands
CEO, President & Director10.3yrsUS$4.36m0.44%
$ 6.1m
Johannes Van Houte
Chief Financial Officer8.8yrsUS$1.61m0.048%
$ 668.8k
Gwenn Hansen
Chief Scientific Officer4.5yrsUS$1.63m0.072%
$ 1.0m
John Kuriyan
Founder & Member of Scientific Advisory Boardno datano datano data
Michael Rapé
Founder & Member of Scientific Advisory Boardno datano datano data
Arthur Weiss
Founder & Member of Scientific Advisory Boardno datano datano data
Rita Kwong
Senior Accounting Managerno datano datano data
Pasit Phiasivongsa
Chief Technical Officerless than a yearno datano data
Christine Ring
Chief Legal Officer5.3yrsUS$1.65m0.040%
$ 557.0k
Eric Schlezinger
Chief People Officer2.3yrsno datano data
Jason Kantor
Chief Business Officer4.4yrsno datano data
Christopher Phelps
Senior VP & Head of Early Drug Discovery3.9yrsno datano data

4.5yrs

Average Tenure

58yo

Average Age

Experienced Management: NRIX's management team is considered experienced (4.5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Arthur Sands
CEO, President & Director10.3yrsUS$4.36m0.44%
$ 6.1m
John Kuriyan
Founder & Member of Scientific Advisory Boardno datano datano data
Michael Rapé
Founder & Member of Scientific Advisory Boardno datano datano data
Arthur Weiss
Founder & Member of Scientific Advisory Boardno datano datano data
Julia Gregory
Independent Chairman5.3yrsUS$238.29k0%
$ 0
Ronald Levy
Member of Medical Advisory Board1.9yrsno datano data
Judith Reinsdorf
Independent Director3.2yrsUS$225.79k0%
$ 0
Roy Baynes
Member of Medical Advisory Boardno datano datano data
Lori Kunkel
Independent Director5.4yrsUS$228.29k0%
$ 0
David Lacey
Independent Director8.7yrsUS$263.29k0.047%
$ 661.0k
Paul Silva
Independent Director3.2yrsUS$225.79k0%
$ 0
Edward Saltzman
Independent Director2.3yrsUS$223.29k0%
$ 0

4.3yrs

Average Tenure

67.5yo

Average Age

Experienced Board: NRIX's board of directors are considered experienced (4.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 21:54
End of Day Share Price 2024/12/20 00:00
Earnings2024/08/31
Annual Earnings2023/11/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Nurix Therapeutics, Inc. is covered by 22 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Brian SkorneyBaird
Joel BeattyBaird
Peter LawsonBarclays